Medtronic (MDT) DIvidends Date & History

Key Takeaways

• Medtronic pays a quarterly dividend of $0.72 per share, translating to an annualized dividend of $2.88 and a dividend yield of approximately 3.46%.
• The company has increased its dividend for 49 consecutive years, placing it one year away from achieving the prestigious Dividend King status (50 or more years of consecutive annual increases).
• The dividend payout ratio stands at roughly 76% of earnings, while the free cash flow payout ratio is approximately 65%, indicating the dividend is well-covered by operating cash generation.
• Medtronic generated $5.2 billion in free cash flow during its 2025 fiscal year, comfortably covering its annual dividend obligations of approximately $3.6 billion.
• With a yield meaningfully above the S&P 500 average, a nearly five-decade growth streak, and a recession-resistant business model, Medtronic appeals to both income-oriented and dividend growth investors.

Dividend Overview

Medtronic (NYSE: MDT), the world's largest medical device manufacturer, maintains a quarterly dividend policy that has become a hallmark of the company's shareholder-friendly capital allocation strategy. As of the most recent declaration in June 2026, the board approved a quarterly cash dividend of $0.72 per ordinary share, marking an increase from the prior $0.71. On an annualized basis, this equates to $2.88 per share. Medtronic pays dividends quarterly, with recent payment dates falling in January, April, July, and October. The most recent ex-dividend date was June 26, 2026, with the payment distributed on July 17, 2026. Medtronic is widely regarded as a premier dividend growth stock rather than a pure high-yield play. Its yield, while attractive, is secondary to the company's extraordinary consistency in raising payouts year after year — a track record that spans nearly half a century.

Dividend History and Growth

Medtronic's dividend history is one of the most durable in the healthcare sector. The company has raised its dividend for 49 consecutive years, a streak that dates back to 1977. The most recent increase, announced in June 2026, raised the quarterly payment from $0.71 to $0.72 per share, representing a modest but symbolically significant 1.4% increase that extended the streak toward the 50-year milestone. Over the past five years, the dividend per share has grown at a compound annual growth rate (CAGR) of roughly 4.8%, reflecting steady, incremental increases. Annual dividend payments have risen from approximately $2.47 per share in fiscal 2021 to $2.84 per share in fiscal 2026, and the newly raised rate points toward $2.88 going forward. Medtronic has never cut its dividend, and each annual increase, while typically modest in percentage terms, has been reliable and predictable — a testament to the company's stable cash flows and disciplined financial management.

Dividend Sustainability and Payout Ratio

Medtronic's dividend appears well-supported by both earnings and free cash flow. The trailing twelve-month earnings-based payout ratio sits at approximately 76%, while the free cash flow payout ratio — often a more relevant measure for capital-intensive businesses — is roughly 65%. During its fiscal 2025 year, Medtronic generated $5.2 billion in free cash flow, providing ample coverage for its roughly $3.6 billion in dividend distributions. The company also invested $2.7 billion in research and development (R&D) and approximately $1.9 billion in capital expenditures during the same period, demonstrating that dividend commitments do not come at the expense of reinvestment in the business. Medtronic's balance sheet further supports dividend sustainability: the debt-to-equity ratio stands at approximately 0.57, and the current ratio, a measure of short-term liquidity, is around 2.42. These metrics suggest the company carries a manageable debt load with sufficient liquidity to maintain its dividend program across economic cycles.

Dividend Compared to Industry Peers

Within the medical device and healthcare technology sector, Medtronic's dividend profile stands out. Many large medtech peers, such as Boston Scientific (BSX), do not pay a regular dividend at all, prioritizing reinvestment and acquisitions instead. Among those that do, Stryker (SYK) offers a yield of approximately 1.1%, while Abbott Laboratories (ABT) yields around 2.0%. Becton Dickinson (BDX) provides a yield near 1.6%. Medtronic's yield of roughly 3.46% is among the highest in the pure-play medical device industry, and its 49-year dividend growth streak is unmatched by virtually any other company in the space. When compared to diversified healthcare giants such as Johnson & Johnson (JNJ), Medtronic offers a competitive yield with a similarly impressive — and in some respects superior — track record of consistent annual increases.

AI Screener

For investors seeking to identify dividend-paying stocks like Medtronic or discover new income-generating opportunities, Tickeron's AI Screener offers a powerful AI-driven stock and ETF discovery platform. The AI Screener enables users to filter thousands of equities using customizable criteria, including industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and fundamental data. Dividend-focused investors can leverage the screener to pinpoint stocks with sustainable payout ratios, strong free cash flow coverage, and consistent dividend growth streaks — all without manually sifting through financial statements. Whether scanning for high-yield opportunities, dividend aristocrats, or breakout candidates with income potential, the AI Screener streamlines the research process and surfaces actionable insights far more efficiently than traditional screening methods. Explore the AI Screener today to build a smarter, data-driven dividend portfolio.

Is This Stock Attractive for Dividend Investors?

Medtronic is likely to appeal most to long-term dividend growth investors and conservative income-oriented investors who prioritize reliability, consistency, and decades of demonstrated commitment to shareholder returns over maximum current yield. The company's 49-year streak of consecutive dividend increases places it in rarefied company and signals a corporate culture that treats the dividend as sacrosanct. The yield of approximately 3.46% is well above the broader market average and competitive within the healthcare sector. For investors seeking high-octane dividend growth rates, Medtronic's annual increases — typically in the low single digits — may feel modest. Similarly, investors chasing double-digit yields will find Medtronic unsuitable. However, for those constructing a portfolio around durable, recession-resistant businesses with predictable cash flows and a near-certain path toward Dividend King status, Medtronic represents a compelling candidate. The company's diversified product portfolio across cardiovascular, neuroscience, medical-surgical, and diabetes segments provides a wide competitive moat and revenue stability that underpins the dividend. While past performance does not guarantee future results, Medtronic's financial profile — strong free cash flow, manageable debt, and consistent earnings — suggests the dividend is well-positioned for continued growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations